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Dear Editor
Allergic Bronchopulmonary Aspergillosis
Mimicking Relapsing Chronic Eosinophilic
Pneumonia in Non−Asthma Patient
ABPA is a complex clinical entity that results from an
allergic immune response to Aspergillus species, and
most often occurs in patients with asthma.1 It is rarely
seen in patients without asthma.2,3 There are no es-
tablished tests to confirm a diagnosis of ABPA. Its di-
agnosis is commonly established based on clinical,
radiologic and immunologic criteria.4,5
A 31-year-old woman was referred to us from a lo-
cal clinic for further evaluation and management of a
one-month-history of productive cough. The patient
had been diagnosed with chronic eosinophilic pneu-
monia (CEP) at our hospital about three years before
based on clinical findings such as elevated serum IgE
(512 IUmL), peripheral eosinophil counts (1,725
mm3) and consolidation with peripheral ground-glass
opacities in the left lower lobe on chest X-ray (Fig. 1
A) and computed tomography (CT) scans (Fig. 1B).
A percutaneous needle aspiration biopsy (PCNAB) at
the site of the consolidation also showed severe
eosinophilic inflammation (Fig. 1C). These clinical
findings were suggestive of CEP. The patient was
treated with systemic steroid for two months and had
follow-up loss after achieving an improvement of
symptoms. Moreover, the patient had no history of al-
lergy and acute asthma attack. On admission, the pa-
tient complained of productive cough with pleuritic
chest pain, hoarseness, and sore throat. On physical
examination, the patient had postnasal drip with cob-
ble stone appearance on oropharynx and coarse
breathing sound with crackles in both lower lung
fields, but had no wheezing.
On laboratory tests, the patient had hemoglobin of
13.0 gdL, white blood cell counts 17,300mm3 with
38.8% neutrophils, 13.8% lymphocytes, 41.9% eosino-
phils, and 5.2% monocytes. In addition peripheral
eosinophil counts were 6,800mm3. On serum bio-
chemistry, the patient had normal liver, kidney and
electrolyte profile. Arterial blood gas analysis
(ABGA) on room air showed pH of 7.41, PaO2 of 63
mmHg, PaCO2 of 34 mmHg, HCO3- of 21.6 mEqL,
and SaO2 of 92%. Serum IgE levels were highly in-
creased (2,576 IUmL). On further evaluation, we
performed IgE multiple allergosorbent assay (MAST)
for major inhalants. Despite a higher titer of IgE,
however, there were no specific allergens. Aspergillus
IgG antibody was equivocal (10 UmL). Pulmonary
function test was normal, showing a forced vital ca-
pacity (FVC) of 3.04 L ( 82% of predicted value ) ,
forced expiratory volume in 1 sec (FEV1) of 2.86 L
(96% of predicted value), and an FEV1FVC of 94%. In
addition, the methacholine challenge test was nega-
tive. On chest radiography, the patient had the con-
solidation of both lower lobes and the right middle
lobe (Fig. 2A). As compared with three years ago,
there was a change in chest radiography (Fig. 1A).
On chest CT scans the patient had consolidations,
mild central bronchiectasis and surrounding ground-
glass opacities in the left lower lobe and the right
middle and lower ones (Fig. 2B) which was not seen
previously (Fig. 1B). One study showed that unless
recognized and appropriately treated, ABPA may
cause significant irreversible changes in the pulmo-
nary functions, including bronchiectasis, could other-
wise be prevented or attenuated so long as they rec-
ognized and treated as the earliest as possible.6,7 Our
case also showed bronchiectatic changes. Clinicians
should also consider the possibility of developing
other eosinophilic disorders in patient who unexpect-
edly had a relapse or require higher doses of gluco-
corticoids to maintain control. 8 We, therefore as-
sumed that we could not make an early diagnosis of
ABPA because we considered bronchial asthma as
one of the diagnostic criteria for ABPA. In addition,
we also assumed that CEP had progressed to ABPA
in the patient working in a dusty environment as the
time elapsed. Actually, there is a possibility that the
patient might have inhaled Aspergillus antigen. More-
over, the patient had maxillary sinusitis on paranasal
radiography, which suggests that the patient might
have been exposed to allergens. In addition, a bron-
choscopy was performed to evaluate endobronchial
lesion. This showed that many whitish to yellowish
nodules with tenacious secretions were mainly pre-
sent at the sites where the right upper bronchus
originates and the right mediobasal segmental bron-
chus. Furthermore, the bronchial washing and biopsy
was performed at the sites where the right medioba-
sal segmental bronchus originates. A transbronchial
lung biopsy (TBLB) was also done in the laterobasal
segment of the left lower lobe. No malignant cells
were observed on washing cytology. Moreover, respi-
ratory viral polymerase chain reactions and bacterial
culture tests were negative. On TBLB at the left
lower lobe, there were some eosinophilic infiltrations.
Besides, on bronchoscopic biopsy at the right lower
lobe, there were reactive hyperplasias of the bron-
chial epithelium accompanied by many branching
fungal hyphae. These findings were suggestive of As-
pergillus species accompanied by eosinophilic infiltra-
tion (Fig. 2C) . To sum it up, our patient had no
asthma, but elevated peripheral eosinophil count,
higher total IgE, equivocal A. fumigatus specific IgG,
biopsy finding, and central bronchiectasis on chest
CT. Immediate cutaneous hyperreactivity to Aspergil-
lus Ag could not be checked. However, even not ful-
fill the diagnostic criteria for ABPA, we could diag-
nose it clinically through above findings. To manage
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Fig.　1　A: Chest X-ray showed the left perihilar oval shaped consolidation. B: Chest computed tomography 
showed consolidation of the left lower lobe accompanied by surrounding ground-glass opacity. C: A percute-
neous needle aspiration biopsy at the site of the consolidation showing severe eosinophilic infi ltrations (H&E 
stain, ×400).
Fig.　2　A: A chest x-ray on admission showed both a patch infi ltrations and ground-glass opacities in both lower 
lung fi elds. B: A chest computed tomography (CT) showed consolidations and ground-glass opacities accompa-
nied by mild central bronchiectatic changes at both lower lobes. C: Histopathologic examination of the broncho-
scopic biopsy specimen showed eosinophilic infi ltrations, reactive hyperplasias of the bronchial epithelium and 
many branching fungal hyphae, being suggestive of Aspergillus species (H&E stain, ×400).
this, the patient was given a three-day course of
three-times-a-day regimen of itraconazole 200 mg,
then a 3-month course of twice-a-day regimen of itra-
conazole 200 mg and a 1-week course of methylpred-
nisolone 1 mgkg. The steroid treatment doses were
gradually tapered in an outpatient setting. Two weeks
later, the symptoms were rapidly improved. This was
accompanied by the chest radiographic findings that
the infiltration and consolidation were decreased. To-
tal IgE concentration, which is a key indicator for as-
sessing the treatment response and relapse, was rap-
idly declined after three months treatment associated
with symptomatic improvement (184 IUmL).9 The
patient underwent no recurrent episodes at a 4-month
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Our case can be summarized as follows:
(1) Based on a clinical, radiologic and pathologic
finding, the patient definitely had CEP on first admis-
sion.
(2) Based on a 3-year non-symptomatic course as
well as good treatment response, the presence of
CEP would be more plausible rather than early misdi-
agnosis of ABPA.
(3) It can be inferred that CEP might have pro-
gressed to ABPA in the patient working in a dusty en-
vironment as the time has elapsed.
Further studies such as long-term follow-up ones
are warranted to examine the relationship between
CEP and ABPA.
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